PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
NORCROSS, Ga. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal quarter, which ended September 30, 2018 , and provided a business update.
View HTML
Toggle Summary Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
NORCROSS, Ga. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial has been accepted for
View HTML
Toggle Summary Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
NORCROSS, Ga. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Conference being held
View HTML
Toggle Summary Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33% in melanoma Providence Portland principal investigator, Dr.
View HTML
Toggle Summary Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
NORCROSS, Ga. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the H.C.
View HTML
Toggle Summary Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update
NORCROSS, Ga. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its second fiscal quarter, which ended June 30, 2018 , and provided a business update.
View HTML
Toggle Summary Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
NORCROSS, Ga. , June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631  titled
View HTML
Toggle Summary Company Profile for Galectin Therapeutics Inc.
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces New CEO
NORCROSS, Ga. , June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin , Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
NORCROSS, Ga. , June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin D.
View HTML